Fluid resuscitation in haemorrhagic shock in combat casualties by unknown
Ravi and Puri  Disaster and Mil Med  (2017) 3:2 
DOI 10.1186/s40696-017-0030-2
REVIEW
Fluid resuscitation in haemorrhagic 
shock in combat casualties
Parli R. Ravi1* and Bipin Puri2
Abstract 
This brief update reviews the recent literature available on fluid resuscitation from hemorrhagic shock and consid-
ers the applicability of this evidence for use in resuscitation of combat casualties in the combat casualty care (CCC) 
environment. A number of changes need to be incorporated in the CCC guidelines: (1) dried plasma (DP) is added as 
an option when other blood components or whole blood are not available; (2) the wording is clarified to emphasize 
that Hetastarch is a less desirable option than whole blood, blood components, or DP and should be used only when 
these preferred options are not available; (3) the use of blood products in certain tactical field care settings where this 
option might be feasible (FSC, GH) is discussed; (4) 1:1:1 damage control resuscitation (DCR) with plasma: packed red 
blood cells (PRBC): platelets is preferred to 1:1 DCR with plasma: PRBC when platelets are available; and (5) the 30-min 
wait between increments of resuscitation fluid administered to achieve clinical improvement or target blood pres-
sure has been eliminated. Also included is an order of precedence for resuscitation fluid options. There should be an 
emphasis on hypotensive resuscitation in order to minimize (1) interference with the body’s hemostatic response and 
(2) the risk of complications of over resuscitation. Hetastarch is retained as the preferred option over crystalloids when 
blood products are not available because of its smaller volume and the potential for long evacuations in the military 
setting.
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Background
About 25% of battle casualties are ‘potentially salvageable’ 
[1]. The single major cause of death over 6 h in this group 
is haemorrhage either as a primary insult or second-
ary to trauma induced coagulopathy. Fluid resuscitation 
of the right type and in the right dose reduces mortal-
ity and morbidity [2]. The concept of fluid resuscitation 
for haemorrhagic shock has changed from large volume 
crystalloid resuscitation, to small volume colloid resus-
citation and use of blood or blood products at the ear-
liest—even as a primary resuscitative fluid and early use 
of anti-fibrinolytic such as tranaxemic acid all of which 
form a part of damage control resuscitation [3]. Damage 
control resuscitation (DCR) comprises of hypotensive 
resuscitation and haemostatic resuscitation which aims 
to achieve the following:
(a)   A restricted increase in intravascular volume target-
ing a systolic blood pressure (SBP) up to 90 mmHg 
(improvement of mental status or a weakly palpable 
radial pulse as a surrogate marker) so as to mini-
mizes adverse effects of edema and prevent dilu-
tional coagulopathy caused by large volume crystal-
loid resuscitation, reduce the incidence of a re-bleed 
due to clot dislodgement (which increasingly occurs 
over systolic blood pressures of 90  mm Hg) while 
maintaining perfusion to vital organs
(b)   Enhance the body’s ability to form and retain a clot 
at bleeding sites
(c)  Optimize oxygen carrying capacity
This commentary reviews the available fluids used in 
resuscitation and correct recommendations in vogue in 
management of combat casualties.
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Fluids used in resuscitation
Crystalloids
Crystalloids in a ratio of 3:1 (3 ml of crystalloid for every 
ml of shed blood) are used commonly as the first line 
of fluid in haemmorghic shock. Crystalloids however, 
have no role in DCR as short term increase in intravas-
cular volume are negated by risk of pulmonary oedema, 
displacement of forming clots at sites of vascular injury, 
abdominal compartment syndrome, acidosis, worsening 
of cerebral oedema, and dilutional coagulopathy [4]. In 
fact there is Level B clinical evidence that large volume 
crystalloid resuscitation reduces survival [5]. If the only 
available fluid is crystalloid then, ringer lactate is pre-
ferred over NS because it does not produce the hyper-
chloremic acidosis and the concern of lactate in RL 
causing acidosis is some what unfounded [6]. Plasma-
lyte A if available offers some benefit over RL [neutral 
ph of 7.4, osmolarity of 295 mosm/l and no calcium. RL 
is more acidic, slightly hypotonic and contains calcium 
which may cause blood to coagulate if used with packed 
red blood cells (PRBC) or whole blood]. Hypertonic 
saline dextran (HSD) and hypertonic saline (HS) improve 
hemodynamic and metabolic responses, modulate 
immune function and reduce brain oedema in a num-
ber of experimental injury models. However a cochrane 
study concluded that there is no evidence that hypertonic 
crystalloids are better than near isotonic crystalloids for 
fluid resuscitation in trauma [7].
Colloids
Colloids [Gelatins, various Hydroxy ethyl starches (HES) 
and albumin] are more effective than crystalloids for 
expanding the plasma volume because they contain large, 
poorly diffusible solute molecules that create an osmotic 
pressure to keep water in the vascular space with less 
extravasation of fluid into the lung than RL with a result-
ing improvement in oxygenation [8]. The smaller vol-
ume of colloids required for an equivalent and extended 
expansion of the intravascular space as compared to crys-
talloids offers a logistical advantage. However their pro-
pensity to cause renal damage is still controversial with 
some studies reporting no renal damage [7] while oth-
ers did [9]. The FIRST trial reported that hydroxyl ethyl 
starch improves the renal function and lactate clear-
ance when used for resuscitation in patients of penetrat-
ing trauma [9]. Additionally high molecular weight HES 
inhibits platelet function with the exception of Hextend 
(HES 130/0.75 in balanced electrolyte solution) which 
has a platelet stimulating effect which may be partially 
due to its solvent containing calcium chloride dehydrate 
[10]. There is Level B evidence that Hextend used in two 
aliquots of 500 ml each to supplement fluid resuscitation 
in trauma patients is safe and does not result in a coagu-
lopathy [11–13]. However, the FDA issued a safety com-
munication on HESs (Hespan, Hextend, and Voluven) in 
November 2013. The warning noted an increased risk in 
mortality and renal replacement therapy associated with 
the use of these products as used to treat critically ill 
patients [14]. However this communication did not men-
tion the use of these products in the prehospital resusci-
tation of trauma patients, nor did it address the known 
increase in mortality and fluid overload complications 
resulting from the alternative use of large volume crys-
talloids in such patients Use of albumin for resuscitation 
in patients with associated traumatic brain injury (TBI) 
resulted in increased mortality [15]. This fact precludes 
its use in combat casualty care as haemorrhagic shock 
and TBI often co-exist.
Blood and blood products
Resuscitation with whole blood, component therapy 
and plasma in that order best fulfil the criteria of DCR 
as they contribute to haemostasis in varying degrees 
while increasing the intravascular volume. There is some 
debate on the ability of Warm fresh whole blood and 
stored whole blood in correcting coagulopathies. Certain 
authors advocate fresh warm whole blood (FWWB) to 
more efficient than component therapy or stored whole 
blood in correcting coagulopathy as it has fresher RBC 
and better functioning and concentration of platelets 
and plasma [16]. The amount of fresh warm whole blood 
transfused is independently associated with improved 
48-h and 30-day survival and the amount of stored red 
blood cells transfused is independently associated with 
decreased 48-h and 30-day survival for patients with 
traumatic injuries that require massive transfusion [17]. 
However few recent studies and reports have shown the 
efficacy of stored whole blood to be as good as FWWB 
[18, 19]. The use of FWWB in combat casualty care may 
be warranted stored whole blood or PRBC at the level of 
the field surgical centre (FSC) since the supply of the lat-
ter is likely to be small and component therapy is unavail-
able. Establishment of walking blood banks at FSC level 
where FWWB can be obtained stored and transfused is 
desirable. FWWB carries the risk of transfusion transmit-
ted diseases which can be minimized by donor screening 
surveys, rapid screening tests of donated products for 
HIV, HCV and Hepatitis B, and pre-donation screening 
of potential donors (when possible) for routinely tested 
TTD’s. In addition all military personnel should be tested 
for HIV and immunized against Hepatitis B prior to 
deployment. Table  1 depicts the combat Casualty Care 
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recommendations for the collection, treatment, and stor-
age of FWWB.
Lyophilized (dried) plasma (DP) is a logistically attrac-
tive option for battlefield trauma care at the RAP as it 
can be stored under a wide range of temperature (2 to 
35 °C) for 15–24 months. The two available brands cur-
rently available and are been used extensively in com-
bat operations are LyoPlas and LyoPhil. DP offers the 
opportunity for both volume replacement and replace-
ment of lost clotting factors and has a good safety 
record [20]. Thirty-eight percentage of combat casu-
alties who require a transfusion have a coagulopathy 
[21] which increases mortality by three to sixfold [22] 
and plasma administration reduces the coagulopathy. 
The German DP product (LyoPlas) is a quarantined, 
single-donor product. When stored at room tempera-
tures for 24 months, the individual coagulation factors 
retain 75–100% of their activity. LyoPlas also enables 
rapid treatment of coagulopathies without the need 
for complex logistics or thawing. Over 230,000 units 
have been transfused to date with no reports of major 
adverse complications to include viral transmission. The 
frequency of transfusion reactions approximates that of 
FFP. LyoPlas is type specific; type AB can be used if the 
recipient’s blood type is unknown. The Israeli Defence 
Force (IDF) has implemented a program to provide DP 
at the point of injury. The IDF program selected the 
German LyoPlas product, and it has now been used at 
the point of injury [20]. Presently this product is not 
available in India. All efforts should be made to ensure 
the availability of this wonderful resuscitative option for 
the Armed Forces. Thus the preferred fluids for DCR in 
haemorrhagic shock in order of preference are as under 
in order of preference:
1. Whole blood
2. 1:1:1 plasma, RBCs, and platelets
3. 1:1 plasma and RBCs
4. Reconstituted DP (not available presently), liquid or 
thawed plasma, alone or RBCs alone
5. Hextend
6. RL or Plasma-Lyte
Combat casualties are initially managed in an austere 
environment and choice of fluid will very often be con-
founded by logistical issues. Guidelines for resuscita-
tion of combat casualties at various echelons First aid 
post and forward surgical centre (FAP and FSC) is given 
in Table  2. None the less all efforts should be made to 
ensure availability of blood, blood products and lyophi-
lized plasma as far forward as possible to ensure best 
possible care to combat casualties. Early use of tourni-
quets, active and passive warming devices and early use 
of tranaxemic acid [22] when indicated play an impor-
tant role in salvaging combat casualties suffering from 
haemorrhagic shock.
Conclusion
Fluid resuscitation strategies for combat casualties need 
to be urgently refined to keep pace with current recom-
mendation. Large volume crystalloid resuscitation which 
is still in vogue in the most situations in combat need to 
be replaced with low volume colloid resuscitation and 
one of plasma or FWWB as forward in the field as pos-
sible to satisfy the arms of DCR namely the hypotensive 
resuscitation and haemostatic concerns. There should be 
a policy to outline planning parameters for blood supply 
to Forward medical echelons. The policy should specify 
zone wise responsibilities at various levels for ensuring 
Table 1 Guidelines for blood collection and storage in com-
bat areas
Donation
 Develop a pre-deployment roster of pedigreed donors (screened every 
90 days)
 ABO and Rh
 Transmissible diseases
  In emergency situations
 Prefer previous and type O donor
 Perform onsite ABO typing
 Perform direct cross-match if possible
Treatment
 Use approved blood recipient set(contains anticoagulant)
 Fill until 650-mL bag is nearly full (approx 450 mL blood)
 Draw cross-match and transmissible disease blood tubes
 Submit to supporting lab even after use of blood
Storage
 Keep fresh warm blood no longer than 24 h
 If less than 8 h old, may be refrigerated for 3 weeks
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Table 2 Guidelines for fluid resuscitation at various field echleons
Fluid resuscitation at level of Combat Zone
Assess for hemorrhagic shock; altered mental status (in the absence of head injury) and weak or absent peripheral (radial)pulses are the best field 
indicators of shock
 a. If not in shock:
  No IV fluids necessary
  PO fluids permissible if conscious and can swallow
 b. If in shock:
  Hextend, 500 mL IV bolus
  Repeat once after 30 min if still in shock
  No more than 1000 mL of Hextend
 c. Continued efforts to resuscitate must be weighed against logistical and tactical considerations and the risk of incurring further casualties
 d. If a casualty with an altered mental status due to suspected TBI has a weak or absent peripheral pulse, resuscitate as necessary to maintain a palpa-
ble radial pulse
Fluid resuscitation at First Aid post
Reassess for hemorrhagic shock (altered mental status in the absence of brain injury and/or change in pulse character.) Maintain target systolic BP 
80–90 mmHg
 a. If not in shock:
  No IV fluids necessary
  PO fluids permissible if conscious and can swallow
 b. If in shock and blood products are not available:
  Resuscitate with Dried Plasma (DP) or if not available
  Simultaneously give 1gm of tranaxemic acid in 100 ml saline
  Hextend 500 mL IV bolus
  Repeat after 30 min if still in shock
  Continue resuscitation with Hextend or crystalloid solution as needed to maintain target
BP or clinical improvement
 c. If in shock and blood products are available under an approved command or theater protocol:
  Resuscitate with whole blood preferably FWWB. Continue resuscitation as needed to maintain target BP or clinical improvement
 d. If a casualty with an altered mental status due to suspected TBI has a weak or absent peripheral pulse, resuscitate as necessary to maintain a palpa-
ble radial pulse. If BP monitoring is available, maintain target systolic BP of at least 90 mmHg
Fluid resuscitation at Field Surgical Centre
 a. The resuscitation fluids of choice for casualties in hemorrhagic shock, listed from most to least preferred, are: whole blood*; plasma, RBCs and plate-
lets in 1:1:1 ratio*; plasma and RBCs in 1:1 ratio; plasma or RBCs alone; Hextend; and crystalloid (lactated Ringer’s or Plasma-Lyte A)
 b. Assess for hemorrhagic shock (altered mental status in the absence of brain injury and/or weak or absent radial pulse)
1. If not in shock:
 No IV fluids are immediately necessary
 Fluids by mouth are permissible if the casualty is conscious and can swallow
2. If in shock and blood products are available under an approved blood product administration protocol:
 Resuscitate with whole blood*, or, if not available
 Plasma, RBCs, and platelets in a 1:1:1 ratio*, or, if not available
 Plasma and RBCs in 1:1 ratio, or, if not available
 Reconstituted dried plasma, liquid plasma or thawed plasma alone or RBCs alone
 Reassess the casualty after each unit. Continue resuscitation until a palpable radialpulse,improved mental status or systolic BP of 80–90 mmHg is 
present
3. If in shock and blood products are not available under an approved combat theater blood product administration protocol due to tactical or logisti-
cal constraints:
 Resuscitate with Hextend, or if not available
 Lactated Ringer’s or Plasma-Lyte A
 Reassess the casualty after each 500 mL IV bolus;
 Continue resuscitation until a palpable radial pulse, improved mental status, or systolic
BP of 80–90 mmHg is present
 Discontinue fluid administration when one or more of the above end points has been achieved
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Table 2 continued
4. Ongoing resuscitation to continue along with damage control surgery (DCS)
5. At any given time all possibilities of MEDEVAC should be considered
